Conor Medsystems

Conor Medsystems Files Lawsuit to Revoke Angiotech Patent

MENLO PARK, Calif., Feb 18, 2005 /PRNewswire-FirstCall via COMTEX/ - Conor Medsystems, Inc. (Nasdaq: CONR) today announced that the company has initiated legal proceedings in the High Court of Justice in the United Kingdom to revoke Angiotech Pharmaceutical's patent (No. EP 0 706 376), which relates to stents coated with paclitaxel and a polymeric carrier.

About Conor Medsystems
Conor Medsystems, Inc. develops innovative controlled vascular drug delivery technologies, and has initially focused on the development of drug eluting stents to treat coronary artery disease. For further information on Conor Medsystems and controlled vascular delivery, visit www.conormed.com.

To the extent that any statements made in this press release deal with information that is not historical, these statements are necessarily forward-looking, including statements related to future results of any legal proceedings. As such, they are subject to the occurrence of many events outside of the company's control and are subject to various risks and uncertainties that could cause the company's results to differ from those expressed in any forward-looking statement including, but not limited to, the substantial uncertainties related to patent litigation and the risk that the outcome of any legal proceedings may not be favorable to the company.

SOURCE Conor Medsystems, Inc.

Michael Boennighausen, Chief Financial Officer of Conor Medsystems, Inc., +1-650-614-4100